- Home
- PMX vs ABEO Comparison
PMX vs ABEO Comparison
Compare PMX & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMX
- ABEO
- Stock Information
- Founded
- PMX 2002
- ABEO 1974
- Country
- PMX United States
- ABEO United States
- Employees
- PMX N/A
- ABEO N/A
- Industry
- PMX Trusts Except Educational Religious and Charitable
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- PMX Finance
- ABEO Health Care
- Exchange
- PMX Nasdaq
- ABEO Nasdaq
- Market Cap
- PMX 233.7M
- ABEO 256.9M
- IPO Year
- PMX N/A
- ABEO 1980
- Fundamental
- Price
- PMX $6.73
- ABEO $5.95
- Analyst Decision
- PMX
- ABEO Strong Buy
- Analyst Count
- PMX 0
- ABEO 6
- Target Price
- PMX N/A
- ABEO $18.00
- AVG Volume (30 Days)
- PMX 101.5K
- ABEO 1.1M
- Earning Date
- PMX 01-01-0001
- ABEO 08-11-2025
- Dividend Yield
- PMX 5.28%
- ABEO N/A
- EPS Growth
- PMX N/A
- ABEO N/A
- EPS
- PMX N/A
- ABEO N/A
- Revenue
- PMX N/A
- ABEO N/A
- Revenue This Year
- PMX N/A
- ABEO N/A
- Revenue Next Year
- PMX N/A
- ABEO $322.37
- P/E Ratio
- PMX N/A
- ABEO N/A
- Revenue Growth
- PMX N/A
- ABEO N/A
- 52 Week Low
- PMX $6.09
- ABEO $3.93
- 52 Week High
- PMX $8.47
- ABEO $7.32
- Technical
- Relative Strength Index (RSI)
- PMX 40.67
- ABEO 51.37
- Support Level
- PMX $6.70
- ABEO $5.66
- Resistance Level
- PMX $6.85
- ABEO $5.99
- Average True Range (ATR)
- PMX 0.06
- ABEO 0.24
- MACD
- PMX -0.01
- ABEO 0.01
- Stochastic Oscillator
- PMX 22.22
- ABEO 74.19
About PMX PIMCO Municipal Income Fund III of Beneficial Interest
PIMCO Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal income tax. The fund portfolio of investments consists of investments in different sectors such as transportation, healthcare, and others.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.